Clasp Therapeutics
Cambridge, US · Founded 2020 · 39 employees on LinkedIn · 6 known investors
Clasp Therapeutics develops off-the-shelf precision T cell engagers (its proprietary pHLАre molecules) that target mutant peptide-HLA complexes displayed on cancer cells, directing T cells to destroy tumors carrying common driver mutations such as KRas. The immuno-oncology company is running a Phase 1 trial (GUARDIAN-101) of its lead candidate CLSP-1025 for hard-to-treat cancers.
Investors · 6
Funding
SEC filings, press & company announcements- Undisclosed amountSeries AMar 2024Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does Clasp Therapeutics do?
- Clasp Therapeutics develops off-the-shelf precision T cell engagers (its proprietary pHLАre molecules) that target mutant peptide-HLA complexes displayed on cancer cells, directing T cells to destroy tumors carrying common driver mutations such as KRas. The immuno-oncology company is running a Phase 1 trial (GUARDIAN-101) of its lead candidate CLSP-1025 for hard-to-treat cancers.
- Who are Clasp Therapeutics's investors?
- Clasp Therapeutics's investors include Catalio Capital Management, LP, Cure Ventures, Vivo Capital, Catalio Capital Management, Novo Holdings, Third Rock Ventures.
- Where is Clasp Therapeutics headquartered?
- Clasp Therapeutics is headquartered in Cambridge, US.